Meeting
2014 ASCO Annual Meeting
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
Authors
Holly Jane Meany
Children's National Medical Center, Washington, DC
Holly Jane Meany , Jeffrey Dome , Pamela S. Hinds , Rochelle Bagatell , Suzanne Shusterman , Brigitte C. Widemann , Emily Stern , Wendy B. London , AeRang Kim , Elizabeth Fox , Carlos Rodriguez-Galindo , Jane E. Minturn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01518413
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10052)
DOI
10.1200/jco.2014.32.15_suppl.10052
Abstract #
10052
Poster Bd #
353
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.
First Author: Steven G. DuBois
Poster
2023 ASCO Annual Meeting
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).
First Author: Álvaro Lassaletta
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk